Does Guilin Layn Natural Ingredients (SZSE:002166) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe

Simply Wall StMay 25 20:59 ET

RheinBio (002166.SZ): 2023 equity distribution 10 distribution of 2 yuan share registration date May 31

On May 24, GLONGHUI (002166.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 2.000000 in cash (tax included) to all shareholders for every 10 shares based on 733,994,754.00 shares after excluding 7,992,071.00 shares of the company's existing total share capital. The share registration date for this equity distribution is May 31, 2024; the exclusive dividend date is June 3, 2024.

Gelonghui FinanceMay 24 08:39 ET

Why Guilin Layn Natural Ingredients' (SZSE:002166) Shaky Earnings Are Just The Beginning Of Its Problems

Guilin Layn Natural Ingredients Corp.'s (SZSE:002166) stock showed strength, with investors undeterred by its weak earnings report. Sometimes, shareholders are willing to ignore soft numbers with the

Simply Wall StMay 4 20:08 ET

The Price Is Right For Guilin Layn Natural Ingredients Corp. (SZSE:002166)

Guilin Layn Natural Ingredients Corp.'s (SZSE:002166) price-to-earnings (or "P/E") ratio of 65.1x might make it look like a strong sell right now compared to the market in China, where around half of

Simply Wall StMay 3 18:33 ET

RheinBio (002166.SZ): The overall gross margin for the whole year is expected to remain within a relatively reasonable margin of 25-30%

Gelonghui, April 29丨RheinBio (002166.SZ) held an online exchange on April 26, 2024 to discuss “Based on the first quarter results, does the company have performance guidelines for the full year 2024?” The company replied that in terms of revenue, we will continue to maintain a 15% -20 growth forecast after considering possible quarterly performance fluctuations. In terms of profit, judging by the gross margin level in the first quarter and the price trend of raw materials this year, the overall gross margin for the whole year is expected to remain within a relatively reasonable margin range of 25-30%.

Gelonghui FinanceApr 29 03:16 ET

Rheinbio (002166.SZ): Currently, the construction of the synthetic biology plant has entered a relatively advanced stage, and it is expected to be put into use in the third quarter

Gelonghui April 29 丨 Rheinland Biotech (002166.SZ) held an online exchange on April 26, 2024, about “What are the company's latest developments in the synthetic biology business?” The company replied that the construction of the synthetic biology plant has now entered a relatively advanced stage and is expected to be put into use in the third quarter. In terms of research and development, R&D projects for full synthesis and enzymatic transformation technology are progressing normally, and phased results have been achieved. In particular, projects to produce some high-value natural sweetener ingredients through enzymatic conversion technology have passed pilot tests, and can be quickly put into production after the factory is completed.

Gelonghui FinanceApr 29 03:13 ET